

A Meeting of the Nutrition Society, hosted by the Scottish Section, was held at the Royal Society of Edinburgh, Edinburgh on 7 and 8 April 2009

Symposium on ‘Frontiers in adipose tissue biology’

New insights into adipose tissue atrophy in cancer cachexia

Chen Bing* and Paul Trayhurn

Obesity Biology Research Unit, School of Clinical Sciences, University of Liverpool, Liverpool L69 3GA, UK

Profound loss of adipose and other tissues is a hallmark of cancer cachexia, a debilitating condition associated with increased morbidity and mortality. Fat loss cannot be attributable to reduced appetite alone as it precedes the onset of anorexia and is much more severe in experimental models of cachexia than in food restriction. Morphological examination has shown marked remodelling of adipose tissue in cancer cachexia. It is characterised by the tissue containing shrunken adipocytes with a major reduction in cell size and increased fibrosis in the tissue matrix. The ultrastructure of ‘slimmed’ adipocytes has revealed severe delipidation and modifications in cell membrane conformation. Although the molecular mechanisms remain to be established, evidence suggests that altered adipocyte metabolism may lead to adipose atrophy in cancer cachexia. Increased lipolysis appears to be a key factor underlying fat loss, while inhibition of adipocyte development and lipid deposition may also contribute. Both tumour and host-derived factors are implicated in adipose atrophy. Zinc- α 2-glycoprotein (ZAG), which is overexpressed by certain malignant tumours, has been identified as a novel adipokine. ZAG transcripts and protein expression in adipose tissue are up regulated in cancer cachexia but reduced with adipose tissue expansion in obesity. Studies *in vitro* demonstrate that recombinant ZAG stimulates lipolysis. ZAG may therefore act locally, as well as systemically, to promote lipid mobilisation in cancer cachexia. Further elucidation of ZAG function in adipose tissue may lead to novel targets for preventing adipose atrophy in malignancy.

Adipose atrophy: Cancer cachexia: Zinc- α 2-glycoprotein

Cancer cachexia

Cachexia is derived from the Greek words ‘kakos’ and ‘hexis’, meaning ‘bad condition’. It is a complex metabolic syndrome that comprises weight loss with reductions in skeletal muscle and adipose tissue mass, anorexia and weakness⁽¹⁾. It usually occurs in chronic diseases such as cancer, chronic obstructive pulmonary disease, chronic heart failure and end-stage renal failure⁽¹⁾. Cachexia not only markedly impairs the quality of life but is associated with increased morbidity and mortality.

Most patients with cancer develop cachexia at some point during the course of their disease and approximately half all patients with cancer have weight loss at diagnosis⁽²⁾. Clinically, cachexia should be suspected if involuntary weight loss of >5% pre-morbid weight occurs within a 6-month period⁽¹⁾. The frequency of weight loss

varies with the type of malignancy, being more common and severe in patients with cancers of the gastrointestinal tract, prostate and lung⁽³⁾. Cachexia has a detrimental effect on cancer treatment as a result of, for example, poor responses to chemotherapy⁽⁴⁾. Weight loss is also a prognostic indicator of decreased survival in patients with cancer^(5,6). It is considered that $\leq 20\%$ of all cancer deaths are directly attributable to cachexia^(2,7).

Evidence is accumulating that cancer cachexia arises from multiple metabolic alterations, such as reduced appetite, increased energy expenditure and tissue breakdown. The main tissues that are affected during the development of cachexia are skeletal muscle and white adipose tissue. The mechanisms of muscle wasting have been the focus of intensive research, with the demonstration of reduced protein synthesis and enhanced proteolysis in experimental models of cachexia and in patients

Abbreviations: UCP, uncoupling protein; ZAG, zinc- α 2-glycoprotein.

***Corresponding author:** Dr Chen Bing, fax +44 151 7065802, email bing@liverpool.ac.uk




Fig. 1. Light microscopy of Sirius Red-stained sections of epididymal adipose tissue from control (A), pair-fed (B) and MAC16 tumour-bearing (C) mice at day 18 after tumour inoculation. (Adapted from Bing *et al.* 2006⁽²⁶⁾.)

with cancer cachexia^(3,8). Although profound loss of adipose tissue is a hallmark of cancer cachexia, much less is known of the underlying cellular and molecular mechanisms. A better understanding of fat depletion in malignancy is crucial for the development of effective treatments for the syndrome. The present article reviews studies on the mechanisms and potential mediators of adipose atrophy in cancer cachexia.

Adipose tissue in metabolic health

It is well documented that adipose tissue plays an important metabolic role by storing TAG in periods when energy input exceeds expenditure and releasing NEFA during energy deprivation⁽⁹⁾. As the largest energy reserve in the body, adipose tissue has a major impact on energy flux, plasma lipid levels and glucose uptake. There is compelling evidence that alterations in adipose tissue mass and metabolism have a major impact on whole-body energy homeostasis⁽¹⁰⁾. It has been shown that too little fat in lipodystrophy, as with too much fat in obesity, is a major risk for insulin resistance, dyslipidaemia and vascular diseases⁽¹¹⁾.

In addition to its primary role as a fuel reservoir, white adipose tissue has been affirmed as a major endocrine organ, since the tissue synthesises and secretes an array of hormones and proteins, termed adipokines⁽¹²⁾. Adipose tissue has extensive cross talk with other organs including the brain, liver and skeletal muscle through these adipokines. Over the last decade a growing number of adipokines have been identified, such as leptin, adiponectin, TNF α , visfatin and chemerin, which act locally in an autocrine and/or paracrine manner and/or as endocrine signals to modulate appetite, nutrient metabolism, insulin sensitivity, inflammation and adipose tissue development^(13–17).

Adipose atrophy in cachexia

Extensive loss of adipose tissue is a prominent feature of cancer cachexia. Although it is not clear whether there

are site differences in fat loss, a study using computed tomography scanning has revealed that patients with cancer cachexia who have gastrointestinal carcinoma have a smaller visceral adipose tissue area than control subjects⁽¹⁸⁾. In a follow-up study of patients with cancer the analysis of body composition (by dual-energy X-ray absorptiometry) has shown that in progressive cancer cachexia the loss of body fat is more rapid than that of lean mass and occurs preferentially from the trunk followed by leg and arm adipose tissue⁽¹⁹⁾. A recent study using retrospective computed tomography scan images of patients with advanced colo-rectal cancer has shown that the most rapid loss of adipose tissues ($\leq 41\%$) occurs within 3 months of death⁽²⁰⁾. Marked falls of $\leq 85\%$ body fat have been observed in patients with lung cancer, which may lead to hyperlipidaemia and insulin resistance as well as complicating anti-tumour therapies^(21,22). With the current escalation in obesity, the paradox of higher BMI as a long-term risk factor but having better survival has been observed in several wasting diseases, including chronic obstructive pulmonary disease, chronic heart failure, end-stage renal failure and cancer⁽²³⁾. A recent study has reported that obesity estimated by an elevated BMI appears to have a protective effect against prostate cancer-specific mortality⁽²⁴⁾.

Fat loss cannot be explained by reduced appetite alone, as it often precedes the onset of anorexia and is much more severe in animal models of cachexia than in food restriction⁽²⁵⁾. This pattern is also observed at the tissue level, as morphological examination has shown marked changes in adipose tissue plasticity in mice with cancer cachexia compared with *ad libitum*-fed and pair-fed controls⁽²⁶⁾. Adipose tissue from tumour-bearing mice contains shrunken adipocytes of various sizes with a dilated interstitial space. Further morphometric analysis has revealed that the adipocyte size is dramatically reduced. In the tissue matrix increased fibrosis is evident with strong collagen-fibril staining (Fig. 1). Moreover, the ultrastructural features of 'slimmed' adipocytes are characterised by severe delipidation and alterations in cell membrane conformation, with irregular cytoplasmic projections and increased

mitochondria that are electron dense. Taken together, these changes illustrate adipose remodelling in cancer cachexia. A recent study of adipose tissue from patients with cancer has also shown tissue atrophy in subjects with cachexia but not in those without cachexia (C Bing and NA Stephens, unpublished results).

Mechanisms of adipose atrophy

Although the molecular basis of adipose atrophy is poorly understood, evidence suggests that fat loss may arise from an enhanced catabolic response and disrupted anabolic processes. Increased lipolysis appears to be a key factor^(27,28). In patients with cancer cachexia there is an increase in glycerol and fatty acid turnover compared with patients with cancer without cachexia⁽²⁹⁾. It has also been shown that whole-body lipolysis, measured by the rate of appearance of glycerol, is higher in patients with cancer who are losing weight than in healthy subjects⁽²⁷⁾. Studies have demonstrated that lipolytic activity (fasting plasma glycerol or fatty acids) is increased in patients with cancer cachexia^(28,30). Increased expression and activity of hormone-sensitive lipase, a rate-limiting enzyme of the lipolytic pathway, is thought to promote lipolysis. Hormone-sensitive lipase mRNA and protein levels have been shown to be increased in adipose tissue of patients with cancer cachexia^(28,31). It is therefore proposed that inhibition of hormone-sensitive lipase may prevent or reverse cachexia-associated fat loss. Furthermore, in mature adipocytes isolated from subcutaneous fat of patients with gastrointestinal adenocarcinoma the lipolytic effects of catecholamines and natriuretic peptide are increased by >2-fold in patients with cachexia, although the basal lipolysis is unchanged⁽²⁸⁾. However, gene expression of adipose TAG lipase is not affected in patients with cachexia⁽²⁸⁾. It is also postulated that the fatty acids liberated by lipolysis may serve as substrates for oxidation⁽³²⁾, which might be mediated by the adipocyte-specific gene cell death-inducing DNA fragmentation factor- α -like effector A. Cell death-inducing DNA fragmentation factor- α -like effector A mRNA levels are increased in patients with cancer cachexia and its overexpression *in vitro* stimulates adipocyte fatty acid oxidation while decreasing glucose oxidation through inactivation of the pyruvate dehydrogenase complex⁽³²⁾.

In addition to increased lipolysis, fat loss may be attributable to a decrease in lipid deposition. Circulating insulin, the hormone that promotes fat deposition and glucose transport in adipose tissue, is reduced in the tumour-bearing state^(33–35). A fall in lipoprotein lipase activity in white fat has been reported in tumour-bearing mice⁽³⁶⁾. This outcome may lead to reduced cleavage of TAG from plasma lipoproteins into glycerol and NEFA for storage, resulting in an increased net flux of lipid into the circulation. There is also evidence that fat diminution in cachexia could be the result of impairment in the formation and development of adipose tissue. A recent study has shown that the expression of the genes encoding several key adipogenic transcription factors, including CCAAT/enhancer-binding protein- α and - β , PPAR γ and sterol regulatory element-binding protein-1c, is markedly reduced in

white fat of mice with cancer cachexia⁽²⁶⁾. mRNA levels of sterol regulatory element-binding protein-1c targets, genes encoding lipogenic enzymes fatty acid synthase, acetyl-CoA carboxylase, stearoyl-CoA desaturase 1 and glycerol-3-phosphate acyl transferase, also fall markedly^(26,37). Finally, glucose, which serves as a substrate for lipid synthesis, is transported into the adipocyte via the insulin-responsive facilitative glucose transporter GLUT-4. However, there is a decrease in GLUT-4 mRNA in white fat of mice with cancer cachexia⁽²⁶⁾, which could be a downstream effect of inhibited CCAAT/enhancer binding protein α since its deficiency is associated with abnormal subcellular localisation of GLUT-4⁽³⁸⁾.

Potential mediators of adipose atrophy

Several factors produced by tumours and host tissues in the presence of a tumour burden are suggested to be able to mediate fat loss in cachexia. These factors include pro-inflammatory cytokines such as TNF α , IL-1 β and IL-6 and the lipid-mobilising factor zinc- α 2-glycoprotein (ZAG; also known as AZGP1), each of which can be derived from the tumour and also from the host tissues. Their potential involvement in cachexia-associated fat depletion will be discussed.

Cytokines

TNF α , also termed cachectin, was first identified as the cachexia-inducing factor in chronic diseases such as cancer and persistent infection⁽³⁹⁾. Recent data have shown that TNF α infusion can induce systemic lipolysis in human subjects⁽⁴⁰⁾. Treatment with TNF α *in vitro* increases glycerol release from rodent and human adipocytes, probably by inhibiting lipoprotein lipase activity⁽⁴¹⁾ and down regulating the expression of perilipin, which then enables hormone-sensitive lipase to access the surface of lipid droplets⁽⁴²⁾. TNF α -induced adipocyte lipolysis is the outcome of activation of the TNF α receptor 1-dependent pathway^(43,44), which involves the stimulation of extracellular signal-regulated kinase 1 and 2, mitogen-activated protein kinase, c-Jun N-terminal kinase and protein kinase A^(45,46). TNF α also has an inhibitory effect on adipocyte differentiation via the Wnt-signalling pathway^(47,48). In addition, both TNF α and IL-1 β are able to inhibit glucose transport in murine and human adipocytes⁽⁴⁹⁾ and consequently decrease the availability of substrates for lipogenesis. Some studies suggest that TNF α also increases lipid deployment, probably via up-regulation of uncoupling protein (UCP) 2 and UCP3 expression in skeletal muscle^(50,51), offering a mechanism to remove NEFA resulting from lipolysis. Although these studies indicate a role for TNF α in reducing fat mass, its importance in cancer-related adipose atrophy is still debatable. It is largely a result of the observations that circulating TNF α levels are unchanged or undetectable^(52,53), as well as elevated^(54,55), in patients with cancer cachexia.

IL-6 has been shown to moderately increase lipolysis in human adipose tissue *in vitro*⁽⁵⁶⁾. Treatment with CNTO-328, a monoclonal antibody to IL-6, is able to reverse

tumour-induced cachexia in nude mice⁽⁵⁷⁾. Recent work has shown that IL-6 is necessary for the onset of adipose and skeletal muscle wasting in the Apc(Min/+) mouse⁽⁵⁸⁾. Despite serum IL-6 levels being elevated in patients with cancer^(59,60), it is still unclear whether circulating IL-6 correlates with the extent of cachexia^(53,59–61). Since TNF α and IL-6 are also produced by adipose tissue, although probably mostly from non-fat cells⁽⁶²⁾, their autocrine and/or paracrine effects may be important in cachexia. However, studies in mice with cancer cachexia have shown that TNF α and IL-6 mRNA levels in white fat are unaffected by the tumour burden^(26,63). In a recent study of patients with gastrointestinal cancer no alterations were found in gene expression of TNF α and IL-6 and their protein release by adipose tissue under cachectic states⁽⁶⁴⁾. In addition, there is no apparent infiltration of macrophages and lymphocytes in adipose tissue of mice with cachexia⁽²⁶⁾ and patients with cancer cachexia⁽⁶⁴⁾.

ZAG, a lipid-mobilising factor

ZAG is a 41 kDa soluble protein first isolated from human plasma⁽⁶⁵⁾ and subsequently identified in secretory epithelial cells, including those of liver, breast, prostate and the gastrointestinal tract⁽⁶⁶⁾. The crystal structure of ZAG reveals that it belongs to the class I MHC family. There is a non-peptidic ligand in the ZAG counterpart of the MHC peptide-binding groove, which may relate to its signalling function⁽⁶⁷⁾. ZAG is overexpressed by several types of malignant tumour, such as breast, prostate and bladder cancers^(37,68,69), and ZAG levels are elevated in serum and seminal fluid of patients with prostate cancer^(37,70). The biological functions of ZAG were largely unknown until a lipid-mobilising factor, purified from the urine of patients with cancer cachexia, was shown to be identical to ZAG in electrophoretic mobility, immunoreactivity and amino acid sequence⁽⁷¹⁾. ZAG has also been purified from a murine adenocarcinoma (MAC16) that induces profound cachexia⁽⁷²⁾. Amino acid sequence analysis has revealed that murine and human ZAG display an overall homology of 59%⁽⁷³⁾, but share up to 100% identity in specific regions thought to be important in lipid metabolism⁽⁶⁷⁾.

Treatment with purified ZAG can cause weight loss in genetically-obese *ob/ob* mice⁽⁷²⁾ and normal mice^(74,75), and body composition analysis indicates that ZAG-induced weight loss is a result of selective reduction in body fat but not lean mass. ZAG has been shown *in vitro* to stimulate glycerol release from isolated murine adipocytes in a dose-dependent manner^(72,75). The lipolytic effect of ZAG has been postulated to be mediated by β 3-adrenoceptors and the activation of the intracellular cAMP pathway. ZAG has been shown to be able to produce a comparable increase in cAMP levels to that obtained with isoprenaline and ZAG-induced lipolysis can be attenuated by the specific β 3-adrenoceptor antagonist SR59230 in adipocytes^(72,75,76).

In addition to lipid mobilisation there is also evidence that ZAG promotes lipid utilisation in brown adipose tissue and skeletal muscle. ZAG administration *in vivo* in mice leads to an up-regulation of UCP1 mRNA and protein expression in brown adipose tissue and of skeletal muscle UCP2 and UCP3 mRNA⁽⁷⁴⁾. ZAG induces expression of

UCP1 protein and O₂ uptake *in vitro* in primary cultures of brown adipose tissue^(72,77). Hence, by up regulating UCP in brown adipose tissue and muscle, ZAG may provide a mechanism for the disposal of excess fatty acids liberated from enhanced lipolysis, which could lead to increased energy expenditure during cachexia.

Adipose-derived ZAG in cancer cachexia

The secretory function of adipose tissue and the potent fat-mobilising effect of ZAG have led to the postulation that this protein could also be produced by adipose tissue, thereby modulating adipocyte metabolism⁽⁷⁸⁾. Work from the authors' group has demonstrated that the ZAG gene and protein are expressed by the major white fat depots (epididymal, perirenal, subcutaneous, mammary gland) and the interscapular brown fat of mice⁽⁷⁸⁾. Further detection using immunocytochemistry has shown the presence of ZAG protein in the cytoplasm of adipocytes in adipose tissue⁽⁷⁸⁾. In human subjects ZAG mRNA and protein have been shown to be expressed in both visceral and subcutaneous fat depots⁽⁷⁸⁾. Furthermore, ZAG mRNA and protein are detected in differentiated human Simpson-Golabi-Behmel syndrome adipocytes. Most importantly, ZAG, which contains a secretory signal sequence⁽³⁷⁾, has been shown to be secreted into the culture medium by differentiated Simpson-Golabi-Behmel syndrome adipocytes⁽⁷⁹⁾. Subsequent quantification of ZAG secretion levels in the culture medium has revealed its concentration to be in the range of ng/ml per 24 h, close to that of adiponectin⁽⁸⁰⁾. Taken together, these findings indicate that ZAG is indeed a novel adipokine produced abundantly by adipocytes and the protein may have a major action locally in the regulation of fat mass.

Adipose-derived ZAG appears to be inversely associated with body fat mass. ZAG mRNA and protein levels are markedly increased in adipose tissue of mice with cancer cachexia and, furthermore, the increase in ZAG protein content is related to the extent of weight loss in these animals⁽⁷⁸⁾. In contrast, as a reference adipokine, leptin mRNA and circulating leptin levels are strikingly repressed in tumour-bearing mice^(26,35,78) (Fig. 2). Very recently, it has been shown that ZAG mRNA and protein expression are also up regulated in adipose tissue in patients with cancer cachexia (T Mracek, NA Stephens, X Xiao and C Bing, unpublished results). Contrarily, studies of obese subjects have shown that ZAG gene expression is down regulated in subcutaneous adipose tissue of obese women⁽⁸¹⁾ and men⁽⁸²⁾. Furthermore, recent work has demonstrated that ZAG mRNA levels are negatively correlated with total fat mass in human subjects with a wide range of BMI⁽⁸⁰⁾.

Although the role of ZAG in adipose tissue remains to be established, its effect on fat loss has been further supported by a recent study that shows that ZAG-knock-out mice are vulnerable to weight gain when fed a high-fat diet and this outcome appears to be the result of decreased lipolytic response to several stimuli, such as isoprenaline, CL316243, forskolin and isobutylmethylxanthine, in adipocytes⁽⁸³⁾. Recent work has demonstrated that recombinant ZAG stimulates lipolysis in human adipocytes (T Mracek,




Fig. 2. mRNA levels of zinc-α2-glycoprotein (A), leptin (B), CCAAT/enhancer-binding protein α (C) and sterol regulatory element-binding protein-1c (D) in epididymal adipose tissue of control (□), pair-fed (PF; ■) and MAC16 tumour-bearing (■) mice, quantified by real-time PCR and normalised to β-actin. Values presented as fold changes relative to controls are means with their standard errors represented by vertical bars for eight mice per group. Mean values were significantly different from those for the control group: * $P < 0.05$, ** $P < 0.01$. Mean values were significantly different from those for the PF group: † $P < 0.05$, †† $P < 0.01$. (Adapted from Bing *et al.* 2006⁽²⁶⁾.)




Fig. 3. A schematic diagram of lipid catabolism in cancer cachexia. Certain tumour and host tissue-produced factors, such as TNFα and zinc-α2-glycoprotein (ZAG), may act systemically and/or as autocrine and/or paracrine signals to stimulate adipocyte lipid metabolism. TNFα-induced lipolysis acts through a TNFα receptor 1 (TNFR-1) dependent pathway, which inhibits perilipin allowing hormone-sensitive lipase (HSL) to access the surface of lipid droplets. ZAG-stimulated lipolysis may be mediated by β3-adrenoceptors (β3AR) and the activation of the intracellular cAMP pathway. NEFA generated by enhanced lipolysis in cachexia may serve as substrates for lipid utilisation through uncoupling proteins (UCP) in brown adipose tissue (BAT) and skeletal muscle. ↑, Increased; ↓, decreased.

P Trayhurn and C Bing, unpublished results). Further studies are required to unravel the nature of the action of ZAG in human cancer cachexia. Overall, current data point to ZAG, as well as TNF α , as a potential candidate for mediating lipid catabolism in cancer cachexia (Fig. 3). Other factors may also be involved in fat loss in malignancy, e.g. macrophage inhibitory cytokine-1, which causes cachexia and a reduction in fat mass via its central effects on appetite⁽⁸⁴⁾. Interestingly, recent work has found that macrophage inhibitory cytokine-1 is also produced by adipocytes and this factor may have autocrine and/or paracrine effects in adipose tissue⁽⁸⁵⁾.

Conclusion

Cancer cachexia, manifested by progressive weight loss, is a metabolic disorder associated with increased morbidity and mortality. Extensive loss of adipose tissue is a prominent feature of cachexia. The marked alterations in adipose morphology indicate tissue atrophy and this outcome cannot be attributable to reduced appetite alone. Evidence suggests that altered adipocyte metabolism may have an important role. Increased lipolysis appears to be a key factor, while impairment in lipid deposition and adipocyte development may also contribute. Adipose atrophy could be mediated by the tumour and/or host-derived factors. TNF α , as a potential mediator, has been linked with increased lipolysis. ZAG, a potent lipid-mobilising factor, has been identified as a novel adipokine and its expression in adipose tissue is up regulated in cancer cachexia. ZAG may therefore act locally, as well as systemically, to promote lipid breakdown. Further elucidation of the function of ZAG in adipose tissue may lead to novel targets for preventing adipose atrophy in malignancy.

Acknowledgement

The authors declare no conflict of interest. This work is being carried out with financial support from the University of Liverpool R&D Fund, the Biotechnology and Biological Sciences Research Council (BBE015379) and the Medical Research Council (87972). C. B. wrote the draft of the article, with subsequent revision from P. T., and C. B. prepared the final version.

References

1. Morley JE, Thomas DR & Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. *Am J Clin Nutr* **83**, 735–743.
2. Tisdale MJ (2002) Cachexia in cancer patients. *Nat Rev Cancer* **2**, 862–871.
3. Tisdale MJ (2005) Molecular pathways leading to cancer cachexia. *Physiology (Bethesda)* **20**, 340–348.
4. Slaviero KA, Read JA, Clarke SJ *et al.* (2003) Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. *Nutr Cancer* **46**, 148–157.
5. Fearon KC, Voss AC & Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. *Am J Clin Nutr* **83**, 1345–1350.

6. Deans DA, Wigmore SJ, de Beaux AC *et al.* (2007) Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. *Br J Surg* **94**, 1501–1508.
7. Skipworth RJ, Stewart GD, Dejong CH *et al.* (2007) Pathophysiology of cancer cachexia: Much more than host-tumour interaction? *Clin Nutr* **26**, 667–676.
8. Argiles JM, Busquets S & Lopez-Soriano FJ (2006) Cytokines as mediators and targets for cancer cachexia. *Cancer Treat Res* **130**, 199–217.
9. Spiegelman BM & Flier JS (2001) Obesity and the regulation of energy balance. *Cell* **104**, 531–543.
10. Bluher M (2005) Transgenic animal models for the study of adipose tissue biology. *Best Pract Res Clin Endocrinol Metab* **19**, 605–623.
11. Rosen ED & Spiegelman BM (2006) Adipocytes as regulators of energy balance and glucose homeostasis. *Nature* **444**, 847–853.
12. Trayhurn P & Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. *Br J Nutr* **92**, 347–355.
13. Mohamed-Ali V, Pinkney JH & Coppack SW (1998) Adipose tissue as an endocrine and paracrine organ. *Int J Obes Relat Metab Disord* **22**, 1145–1158.
14. Ahima RS & Flier JS (2000) Adipose tissue as an endocrine organ. *Trends Endocrinol Metab* **11**, 327–332.
15. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ *et al.* (2001) The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. *Am J Physiol Endocrinol Metab* **280**, E827–E847.
16. Rajala MW & Scherer PE (2003) Minireview: The adipocyte – at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology* **144**, 3765–3773.
17. Trayhurn P & Bing C (2006) Appetite and energy balance signals from adipocytes. *Philos Trans R Soc Lond B Biol Sci* **361**, 1237–1249.
18. Ogiwara H, Takahashi S, Kato Y *et al.* (1994) Diminished visceral adipose tissue in cancer cachexia. *J Surg Oncol* **57**, 129–133.
19. Fouladiun M, Korner U, Bosaeus I *et al.* (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care – correlations with food intake, metabolism, exercise capacity, and hormones. *Cancer* **103**, 2189–2198.
20. Lieffers JR, Mourtzakis M, Hall KD *et al.* (2009) A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. *Am J Clin Nutr* **89**, 1173–1179.
21. Fearon KC & Preston T (1990) Body composition in cancer cachexia. *Infusionstherapie* **17**, Suppl. 3, 63–66.
22. Fearon KC (1992) The mechanisms and treatment of weight loss in cancer. *Proc Nutr Soc* **51**, 251–265.
23. Kalantar-Zadeh K, Horwich TB, Oreopoulos A *et al.* (2007) Risk factor paradox in wasting diseases. *Curr Opin Clin Nutr Metab Care* **10**, 433–442.
24. Halabi S, Ou SS, Vogelzang NJ *et al.* (2007) Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. *Cancer* **110**, 1478–1484.
25. Ishiko O, Nishimura S, Yasui T *et al.* (1999) Metabolic and morphologic characteristics of adipose tissue associated with the growth of malignant tumors. *Jpn J Cancer Res* **90**, 655–659.
26. Bing C, Russell S, Becket E *et al.* (2006) Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. *Br J Cancer* **95**, 1028–1037.

27. Zuijdgheest-van Leeuwen SD, van den Berg JW, Wattimena JL *et al.* (2000) Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. *Metabolism* **49**, 931–936.
28. Agustsson T, Ryden M, Hoffstedt J *et al.* (2007) Mechanism of increased lipolysis in cancer cachexia. *Cancer Res* **67**, 5531–5537.
29. Shaw JH & Wolfe RR (1987) Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. *Ann Surg* **205**, 368–376.
30. Drott C, Persson H & Lundholm K (1989) Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. *Clin Physiol* **9**, 427–439.
31. Thompson MP, Cooper ST, Parry BR *et al.* (1993) Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. *Biochim Biophys Acta* **1180**, 236–242.
32. Laurencikiene J, Stenson BM, Arvidsson Nordstrom E *et al.* (2008) Evidence for an important role of CIDEA in human cancer cachexia. *Cancer Res* **68**, 9247–9254.
33. Yoshikawa T, Noguchi Y, Satoh S *et al.* (1997) Insulin resistance and the alterations of glucose transporter-4 in adipose cells from cachectic tumor-bearing rats. *JPEN J Parenter Enteral Nutr* **21**, 347–349.
34. Inadera H, Nagai S, Dong HY *et al.* (2002) Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model. *Int J Cancer* **101**, 37–45.
35. Bing C, Taylor S, Tisdale MJ *et al.* (2001) Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. *J Neurochem* **79**, 1004–1012.
36. Thompson MP, Koons JE, Tan ET *et al.* (1981) Modified lipoprotein lipase activities, rates of lipogenesis, and lipolysis as factors leading to lipid depletion in C57BL mice bearing the preputial gland tumor, ESR-586. *Cancer Res* **41**, 3228–3232.
37. Hale LP, Price DT, Sanchez LM *et al.* (2001) Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. *Clin Cancer Res* **7**, 846–853.
38. Rosen ED (2005) The transcriptional basis of adipocyte development. *Prostaglandins Leukot Essent Fatty Acids* **73**, 31–34.
39. Cerami A, Ikeda Y, Le Trang N *et al.* (1985) Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). *Immunol Lett* **11**, 173–177.
40. Plomgaard P, Fischer CP, Ibfelt T *et al.* (2008) Tumor necrosis factor- α modulates human in vivo lipolysis. *J Clin Endocrinol Metab* **93**, 543–549; Epublication 20 November 2007.
41. Yang JY, Koo JH, Yoon HY *et al.* (2007) Effect of scopoletin on lipoprotein lipase activity in 3T3-L1 adipocytes. *Int J Mol Med* **20**, 527–531.
42. Ryden M & Arner P (2007) Tumour necrosis factor- α in human adipose tissue – from signalling mechanisms to clinical implications. *J Intern Med* **262**, 431–438.
43. Lopez-Soriano J, Llovera M, Carbo N *et al.* (1997) Lipid metabolism in tumour-bearing mice: studies with knockout mice for tumour necrosis factor receptor 1 protein. *Mol Cell Endocrinol* **132**, 93–99.
44. Sethi JK, Xu H, Uysal KT *et al.* (2000) Characterisation of receptor-specific TNF α functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. *FEBS Lett* **469**, 77–82.
45. Ryden M, Dicker A, van Harmelen V *et al.* (2002) Mapping of early signaling events in tumor necrosis factor- α -mediated lipolysis in human fat cells. *J Biol Chem* **277**, 1085–1091.
46. Zhang HH, Halbleib M, Ahmad F *et al.* (2002) Tumor necrosis factor- α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. *Diabetes* **51**, 2929–2935.
47. Hammarstedt A, Isakson P, Gustafson B *et al.* (2007) Wnt-signaling is maintained and adipogenesis inhibited by TNF α but not MCP-1 and resistin. *Biochem Biophys Res Commun* **357**, 700–706.
48. Cawthorn WP, Heyd F, Hegyi K *et al.* (2007) Tumour necrosis factor- α inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. *Cell Death Differ* **14**, 1361–1373.
49. Hauner H, Petruschke T, Russ M *et al.* (1995) Effects of tumour necrosis factor α (TNF α) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. *Diabetologia* **38**, 764–771.
50. Masaki T, Yoshimatsu H, Chiba S *et al.* (1999) Tumor necrosis factor- α regulates in vivo expression of the rat UCP family differentially. *Biochim Biophys Acta* **1436**, 585–592.
51. Busquets S, Carbo N, Almendro V *et al.* (2001) Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia? *FEBS Lett* **505**, 255–258.
52. Kayacan O, Karnak D, Beder S *et al.* (2006) Impact of TNF- α and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. *Am J Clin Oncol* **29**, 328–335.
53. Iwase S, Murakami T, Saito Y *et al.* (2004) Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. *Eur Cytokine Netw* **15**, 312–316.
54. Karayiannakis AJ, Syrigos KN, Polychronidis A *et al.* (2001) Serum levels of tumor necrosis factor- α and nutritional status in pancreatic cancer patients. *Anticancer Res* **21**, 1355–1358.
55. Fortunati N, Manti R, Birocco N *et al.* (2007) Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. *Oncol Rep* **18**, 1521–1527.
56. Trujillo ME, Sullivan S, Harten I *et al.* (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. *J Clin Endocrinol Metab* **89**, 5577–5582.
57. Zaki MH, Nemeth JA & Trikha M (2004) CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. *Int J Cancer* **111**, 592–595.
58. Baltgalvis KA, Berger FG, Pena MM *et al.* (2008) Interleukin-6 and cachexia in ApcMin/+ mice. *Am J Physiol Regul Integr Comp Physiol* **294**, R393–R401.
59. Richey LM, George JR, Couch ME *et al.* (2007) Defining cancer cachexia in head and neck squamous cell carcinoma. *Clin Cancer Res* **13**, 6561–6567.
60. Krzystek-Korpacka M, Matusiewicz M, Diakowska D *et al.* (2007) Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF- α , VEGF-A, VEGF-C and midkine in gastro-esophageal cancer patients. *Clin Biochem* **40**, 1353–1360.
61. Kuroda K, Nakashima J, Kanao K *et al.* (2007) Interleukin 6 is associated with cachexia in patients with prostate cancer. *Urology* **69**, 113–117.
62. Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in

- obesity and primarily due to the nonfat cells. *Vitam Horm* **74**, 443–477.
63. Bing C, Brown M, King P *et al.* (2000) Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. *Cancer Res* **60**, 2405–2410.
 64. Ryden M, Agustsson T, Laurencikiene J *et al.* (2008) Lipolysis – not inflammation, cell death, or lipogenesis – is involved in adipose tissue loss in cancer cachexia. *Cancer* **113**, 1695–1704.
 65. Burgi W & Schmid K (1961) Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. *J Biol Chem* **236**, 1066–1074.
 66. Tada T, Ohkubo I, Niwa M *et al.* (1991) Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. *J Histochem Cytochem* **39**, 1221–1226.
 67. Sanchez LM, Chirino AJ & Bjorkman P (1999) Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. *Science* **283**, 1914–1919.
 68. Diez-Itza I, Sanchez LM, Allende MT *et al.* (1993) Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. *Eur J Cancer* **29A**, 1256–1260.
 69. Irmak S, Tilki D, Heukeshoven J *et al.* (2005) Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. *Proteomics* **5**, 4296–4304.
 70. Hassan MI, Kumar V, Kashav T *et al.* (2007) Proteomic approach for purification of seminal plasma proteins involved in tumor proliferation. *J Sep Sci* **30**, 1979–1988.
 71. Todorov PT, McDevitt TM, Meyer DJ *et al.* (1998) Purification and characterization of a tumor lipid-mobilizing factor. *Cancer Res* **58**, 2353–2358.
 72. Hirai K, Hussey HJ, Barber MD *et al.* (1998) Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. *Cancer Res* **58**, 2359–2365.
 73. Ueyama H, Naitoh H & Ohkubo I (1994) Structure and expression of rat and mouse mRNAs for Zn-alpha 2-glycoprotein. *J Biochem (Tokyo)* **116**, 677–681.
 74. Bing C, Russell ST, Beckett EE *et al.* (2002) Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. *Br J Cancer* **86**, 612–618.
 75. Russell ST, Zimmerman TP, Domin BA *et al.* (2004) Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. *Biochim Biophys Acta* **1636**, 59–68.
 76. Russell ST, Hirai K & Tisdale MJ (2002) Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. *Br J Cancer* **86**, 424–428.
 77. Sanders PM & Tisdale MJ (2004) Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage. *Br J Cancer* **90**, 1274–1278.
 78. Bing C, Bao Y, Jenkins J *et al.* (2004) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. *Proc Natl Acad Sci USA* **101**, 2500–2505.
 79. Bao Y, Bing C, Hunter L *et al.* (2005) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. *FEBS Lett* **579**, 41–47.
 80. Mracek T, Ding Q, Tzanavari T *et al.* (2009) The adipokine zinc-alpha2-glycoprotein is downregulated with fat mass expansion in obesity. *Clin Endocrinol (Oxf)* (Epublication ahead of print version; doi: 10.1111/j.1365-2265.2009.03658.x).
 81. Dahlman I, Kaaman M, Olsson T *et al.* (2005) A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. *J Clin Endocrinol Metab* **90**, 5834–5840.
 82. Marrades MP, Martinez JA & Moreno-Aliaga MJ (2008) ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. *J Physiol Biochem* **64**, 61–66.
 83. Rolli V, Radosavljevic M, Astier V *et al.* (2007) Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. *FEBS Lett* **581**, 394–400.
 84. Johnen H, Lin S, Kuffner T *et al.* (2007) Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. *Nat Med* **13**, 1333–1340.
 85. Ding Q, Mracek T, Gonzalez-Muniesa P *et al.* (2009) Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. *Endocrinology* **150**, 1688–1696.